---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-088527"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:28:14.075579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath's CHOPIN trial published: PHP+immunotherapy shows 54.7% vs 15.8% 1-year PFS

## Summary
- 1-year PFS 54.7% vs 15.8% (adjusted HR 0.34; p=0.0002); median PFS 12.8 vs 8.3 months.
- Median OS 23.1 vs 19.6 months (HR 0.39; p=0.0065); 2-year OS 49.6% vs 22.1%.
- Objective response rate 76.3% vs 39.5%; complete response rate 13% vs 3%.
- Grade ≥3 treatment-related AEs 82% (combo) vs 41% (PHP alone); one treatment-related death in combo arm.

## SEC filing metadata
- accession: 0001193125-26-088527
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312526088527/0001193125-26-088527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312526088527/d16781d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-088527
- JSON: https://secwatch.observer/filing/0001193125-26-088527.json
- Plain text: https://secwatch.observer/filing/0001193125-26-088527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.